# Immunovant (IMVT) — Analyst Forecast

IMVT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imvt/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 4 | 0 | 17 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 4, 2026 | JP Morgan | Maintained | Overweight | $50.00 |
| Jun 30, 2026 | Citigroup | Maintained | Buy | $61.00 |
| May 26, 2026 | Guggenheim | Maintained | Buy | $62.00 |
| May 22, 2026 | Truist Securities | Maintained | Hold | $30.00 |
| May 21, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| May 21, 2026 | B of A Securities | Maintained | Buy | $43.00 |
| Apr 15, 2026 | Goldman Sachs | Maintained | Neutral | $32.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Feb 9, 2026 | Guggenheim | Maintained | Buy | $44.00 |
| Jan 8, 2026 | Truist Securities | Maintained | Hold | $22.00 |
| Jan 6, 2026 | Wolfe Research | Upgraded | Peer Perform → Outperform | $50.00 |
| Dec 15, 2025 | Goldman Sachs | Maintained | Neutral | $28.00 |
| Oct 14, 2025 | Truist Securities | Initiated Coverage | Hold | $16.00 |
| Sep 30, 2025 | JP Morgan | Maintained | Overweight | $33.00 |
| Sep 4, 2025 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Aug 12, 2025 | B of A Securities | Maintained | Buy | $30.00 |
| Aug 12, 2025 | JP Morgan | Maintained | Overweight | $37.00 |
| Jul 28, 2025 | UBS | Maintained | Neutral | $18.00 |
| Apr 22, 2025 | UBS | Downgraded | Buy → Neutral | $17.00 |
| Mar 20, 2025 | B of A Securities | Maintained | Buy | $33.00 |

## Frequently Asked Questions

### Is IMVT a buy, sell, or hold?

Analysts covering Immunovant currently average a Buy rating: 13 buy, 4 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on IMVT?

On Aug 4, 2026, JP Morgan maintained Immunovant at Overweight with a price target of $50.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).